Mathew Blackman Stock Analyst Profile - Stifel Research Coverage - Stocknear

Mathew Blackman

Stock Analyst at Stifel

(4.69)
# 1333
Out of 5,504 analysts
69
Total ratings
Success rate
Average return

17 Stocks

Name Action PT Current % Upside Ratings Updated
INGN Inogen
Maintains: Hold
10 7
8.66 -19.17% 12 May 8, 2025
TNDM Tandem Diabetes Care
Maintains: Buy
60 31
14.75 110.17% 6 May 1, 2025
PEN Penumbra
Maintains: Strong Buy
301 318
256.86 23.8% 2 Apr 24, 2025
CLPT ClearPoint Neuro
Maintains: Strong Buy
19 25
27.36 -8.63% 3 Apr 1, 2025
BBNX Beta Bionics
Initiates Coverage On: Buy
25
22.25 12.36% 1 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
245 293
308.85 -5.13% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
92 94
60.5 55.37% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
18 24
14.63 64.05% 5 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 3
1.58 89.87% 1 Oct 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Hold
50
n/a n/a 1 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
90 100
67.06 49.12% 11 Aug 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
19 16
13.96 14.61% 5 Aug 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
18 11
9.09 21.01% 4 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10
n/a n/a 3 Jan 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 16
n/a n/a 2 Mar 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
64
n/a n/a 1 Oct 20, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
30
n/a n/a 2 Aug 26, 2020